Skip to main content

Afreen Idris Shariff

Associate Professor of Medicine
Medicine, Endocrinology, Metabolism, and Nutrition

Overview


Afreen Shariff, MD is an endocrinologist with expertise in endocrine disease in cancer patients. She is the Director of the Duke Onco Endocrinology Program and an Associate Director for the Cancer Therapy Toxicity Program at the Duke Center for Cancer Immunotherapy. She holds a faculty appointment as an Associate Professor of Medicine in the Division of Endocrinology, Diabetes and Metabolism at Duke University School of Medicine.

Dr. Shariff completed her medical school in India from Deccan College of Medical Sciences, Internal Medicine training from East Carolina University’s Brody School of Medicine and fellowship in Endocrinology from Duke University School of Medicine. Her clinical work and research is focused on high value care for endocrine disease in cancer patients.

She was the founding chair the Oncoendocrinology Special Interest Group (SIG) at the Endocrine Society and influences global networking, clinical practice and education in the field of Oncoendocrinology. At Duke, Dr. Shariff's work includes developing interdisciplinary partnerships, creating the clinical infrastructure and framework needed for AI assisted clinical decision making to improve access and coordinated care for patients with cancer therapy related toxicities. She also hosts and produces the podcast series Checkpoint NOW that emphasizes shared decision making between oncologists and subspecialists.

Current Appointments & Affiliations


Associate Professor of Medicine · 2024 - Present Medicine, Endocrinology, Metabolism, and Nutrition, Medicine
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published November 13, 2025
Obesity Weakens Cancer Immunity: Can GLP-1 Drugs Turn It Back On?
Published January 15, 2021
Checkpoint NOW podcast launch
Published November 13, 2020
What to Know If You’re Going to Buy Black Market Insulin

View All News

Recent Publications


Rare irAEs associated with immune checkpoint inhibitor therapy.

Journal Article Expert Opin Drug Saf · February 16, 2026 INTRODUCTION: Immune checkpoint inhibitors (ICIs), although revolutionary in the field of oncology, have been associated with immune-related adverse events (irAEs) that affect nearly every organ of the body. Many common AEs are well documented, but in this ... Full text Link to item Cite

Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors.

Journal Article J Immunother Cancer · October 15, 2025 Immune checkpoint inhibitors (ICIs) are an important class of cancer treatment. Endocrine immune-related adverse events (E-irAEs) account for a significant proportion of irAEs in ICI-treated patients. Diagnosing E-irAEs accurately and timely can be challen ... Full text Link to item Cite
View All Publications

Education


University of Hyderabad (India) · 2008 M.B.B.S.